Amrutanjan Health Care Ltd

₹ 682 -1.16%

26 Apr - close price

amrutanjan.com BSE: 590006 NSE : AMRUTANJAN

About

AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. ^[1]

Key Points

High Market Share in Modern Trade
Amrutanjan has maintained the No. 1 rank in Modern Trade in Head Category with the volume market share of 41.1%* in CY19. ^[1]

Website BSE NSE

Market Cap ₹ 1,970 Cr.
Current Price ₹ 682
High / Low ₹ 775 / 556
Stock P/E 96.7
Book Value ₹ 37.2
Dividend Yield 0.67 %
ROCE 31.4 %
ROE 20.0 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 33.0%

Cons

Stock is trading at 18.3 times its book value
The company has delivered a poor sales growth of 11.8% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone




Operating Profit
OPM %

Interest
Depreciation
Profit before tax
Tax %

EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016
	67	69	71	87	86	101	136	131	134	158	177
	53	53	60	182	76	88	118	113	112	134	145
Operating Profit	13	16	11	-95	10	13	18	17	22	24	31
OPM %	20%	23%	16%	-109%	12%	13%	13%	13%	16%	15%	18%
	1	-2	0	220	10	5	4	4	3	4	5
Interest	1	1	1	0	0	1	3	2	2	1	0
Depreciation	3	2	2	2	1	2	3	4	4	3	3
Profit before tax	11	11	9	123	19	15	16	15	19	24	33
Tax %	45%	46%	42%	25%	38%	34%	39%	35%	36%	38%	37%
	6	6	5	92	11	10	10	10	12	15	21
EPS in Rs				29.80			3.32	3.47	4.26	5.10	7.05
Dividend Payout %	22%	32%	45%	19%	40%	45%	45%	43%	38%	34%	27%

Compounded Sales Growth
10 Years:	10%
5 Years:	12%
3 Years:	11%
TTM:	12%

Compounded Profit Growth
10 Years:	13%
5 Years:	15%
3 Years:	27%
TTM:	37%

Stock Price CAGR
10 Years:	26%
5 Years:	17%
3 Years:	2%
1 Year:	13%

Return on Equity
10 Years:	15%
5 Years:	15%
3 Years:	17%
Last Year:	20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016
Equity Capital	3	3	3	3	3	3	3	3	3	3	3
Reserves	15	20	23	90	94	98	74	79	86	92	106
	6	8	8	1	1	30	22	15	8	2	2
	13	10	14	17	20	26	25	27	23	26	29
Total Liabilities	37	41	48	111	118	157	124	124	120	124	140
	16	13	20	16	16	52	33	30	27	24	29
CWIP	0	3	3	2	7	0	1	1	1	4	1
Investments	0	0	0	0	46	42	29	25	9	9	9
	21	26	25	92	50	62	62	69	83	87	102
Total Assets	37	41	48	111	118	157	124	124	120	124	140

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016
	10	11	5	6	11	6	4	9	17	18	21
	3	-4	-8	89	-47	-29	14	13	16	-5	4
	-12	-1	-2	-30	-8	20	-27	-14	-14	-12	-13
Net Cash Flow	1	6	-5	65	-43	-4	-9	8	20	1	12

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016
Debtor Days	42	26	40	54	43	43	47	79	68	64	57
Inventory Days	93	121	117	52	84	87	74	66	56	50	49
Days Payable	80	76	76	69	122	90	76	56	44	45	51
Cash Conversion Cycle	55	71	81	37	5	40	45	88	80	69	55
Working Capital Days	48	52	67	44	36	42	51	71	65	50	55
ROCE %		54%	29%	28%	18%	14%	16%	18%	23%	26%	31%

Shareholding Pattern

Numbers in percentages

2 Recently

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	50.02%	50.02%	50.02%	50.02%	50.02%	50.02%	50.02%	50.03%	50.03%	50.59%	50.59%	50.59%
	1.50%	1.53%	1.83%	1.43%	1.42%	0.87%	0.76%	0.68%	0.69%	0.75%	0.80%	1.38%
	7.50%	6.94%	6.14%	6.14%	6.16%	6.30%	6.39%	7.18%	7.22%	7.10%	7.24%	7.29%
	40.92%	41.41%	41.90%	42.23%	42.21%	42.62%	42.65%	41.93%	41.87%	41.39%	41.19%	40.66%
	0.06%	0.10%	0.11%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.07%
No. of Shareholders	33,717	41,640	61,367	67,323	66,173	71,064	72,104	69,947	71,428	72,002	68,404	62,664

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	50.09%	50.02%	50.02%	50.02%	50.02%	50.02%	50.03%	50.59%
	0.31%	1.09%	1.93%	4.69%	2.00%	1.43%	0.68%	1.38%
	2.79%	5.68%	8.73%	8.12%	7.76%	6.14%	7.18%	7.29%
	46.80%	43.20%	39.32%	37.17%	40.16%	42.23%	41.93%	40.66%
	0.00%	0.00%	0.00%	0.00%	0.06%	0.18%	0.18%	0.07%
No. of Shareholders	18,427	16,140	18,226	21,207	29,474	67,323	69,947	62,664

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Feb 2024

Transcript

Notes
PPT
Nov 2023

Transcript

Notes
PPT
Aug 2023

Transcript

Notes
PPT
Jun 2023

Transcript

Notes
PPT
Feb 2023

Transcript

Notes
PPT
Nov 2022

Transcript

Notes
PPT
Aug 2022

Transcript

Notes
PPT
May 2022

Transcript

Notes
PPT
Feb 2022

Transcript

Notes
PPT
Nov 2021

Transcript

Notes
PPT
Aug 2021

Transcript

Notes
PPT
May 2021

Transcript

Notes
PPT
Feb 2021

Transcript

Notes
PPT
Nov 2020

Transcript

Notes
PPT
Aug 2020

Transcript

Notes
PPT
Jun 2020

Transcript

Notes
PPT
Feb 2020

Transcript

Notes
PPT
Feb 2020

Transcript

Notes
PPT
Nov 2019

Transcript

Notes
PPT
Aug 2019

Transcript

Notes
PPT
May 2019

Transcript

Notes
PPT